Gasporox (GPX) Q4 2025 earnings summary

Executive summary

• Achieved record sales in Q4 2025 with net revenue of 11,291 KSEK, marking a strong recovery and the company's best quarter to date.

• Q4 operating income reached 1,396 KSEK, a turnaround from -1,085 KSEK in Q4 2024, and EBITDA was 3,050 KSEK.

• Full-year 2025 revenue was 31,573 KSEK, down from 34,104 KSEK in 2024, with a negative operating result of -6,089 KSEK.

• Major deliveries in Q4 were to the pharmaceutical and food industries, with significant growth in the service business.

• Strategic steps included a capital raise, new product launches, and expansion into new markets and segments.

Financial highlights

• Q4 net revenue: 11,291 KSEK (up from 8,007 KSEK year-over-year).

• Q4 operating income: 1,396 KSEK (vs. -1,085 KSEK year-over-year); Q4 EBITDA: 3,050 KSEK.

• Full-year net revenue: 31,573 KSEK (down from 34,104 KSEK year-over-year).

• Full-year operating income: -6,089 KSEK (vs. -2,183 KSEK year-over-year); full-year EBITDA: 335 KSEK.

• Cash flow for Q4: -3,838 KSEK; full-year: -162 KSEK.

• Cash and cash equivalents at year-end: 6,651 KSEK.

Outlook and guidance

• 2026 expected to be eventful with several product launches, including the first inline vial inspection machine and expanded offerings for both pharma and food sectors.

• Continued focus on innovation, market expansion, and strengthening presence in new geographies such as India, Turkey, and parts of Europe.

• No dividend proposed for 2025.